Introgen makes appointment to board
This article was originally published in Scrip
Executive Summary
Introgen Therapeutics, a US biopharmaceutical company focused on the discovery, development and commercialisation of targeted molecular therapies for cancer and other diseases, has elected Dr James Rothman to its board of directors. In September, Dr Rothman, who is renowned for discovering the molecular machinery responsible for transfer of materials among compartments within cells, will relocate his laboratory from Columbia University to Yale University, where he will serve as the Wallace professor of biomedical sciences, chairman of the department of cell biology and founder of the Yale University Center for High-Throughput Cell Biology.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.